Dapsone Formulation C

DRUG2 trials

Sponsors

Allergan

Conditions

Acne Vulgaris

Phase 1

Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

CompletedNCT01773122

AllerganAcne Vulgaris

Start: 2013-01-21End: 2013-05-05Updated: 2019-04-24

An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

WithdrawnNCT01785836

AllerganAcne Vulgaris

Start: 2013-03-31End: 2013-10-31Updated: 2013-02-25